



Date: 09th September 2022

EudraCT No.: 2020-001265-36
Protocol No.: UCDCRC/20/01
Protocol title: COVIRL-001 - A multicentre, prospective, randomised trial comparing standard of care (SOC) alone, SOC plus hydroxychloroquine monotherapy or SOC plus a combination of hydroxychloroquine and azithromycin in the treatment of non-critical, SARS-CoV-2 PCR-positive population not requiring immediate resuscitation or ventilation but who have evidence of clinical decline.
Sponsor: University College Dublin

Premature Termination Statement

For and on behalf of UCD, please be advised that the above referenced trial did not commence due to request made to the sponsor from the Health Products Regulatory Authority (Ireland), based on newly-developed risk related to the use of hydroxychloroquine in the treatment of COVID-19. Due to this the trial was terminated prematurely and did not proceed to enroll any patients. The end of study date is 24th June 2020.

As the study did not begin on site, none of the sites were initiated, no patients were enrolled into the study and no clinical trial data was collected, there will be no scope to provide study results within EudraCT. Please consider the trial terminated and closed.

Sincerely,

Professor Peter Doran

Vice Principal, Research, Innovation & Impact, UCD College of Health & Agricultural Science
Associate Dean, Research, Innovation & Impact, UCD School of Medicine
Director, UCD Clinical Research Centre